Article citationsMore>>

Avan, A., Quint, K., Nicolini, F., Funel, N., Frampton, A., Maftouh, M., Pelliccioni, S., Schuurhuis, G.J., Peters, G.J. and Giovannetti, E. (2013) Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer. Current Pharmaceutical Design, 19, 940-950.
http://dx.doi.org/10.2174/138161213804547312

has been cited by the following article:

• TITLE: EMT and Anti-EMT Strategies in Cancer

  AUTHORS: M. A. Nezami, Steven Hager, Jessica Garner

  KEYWORDS: Cancer, EMT, Anti-EMT, Epigenetic, CTC, ctDNA

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.11, October 29, 2015

  ABSTRACT: This article discusses the role of epithelial mesenchymal transition (EMT) and addresses the scientific merits on epigenetic regulation of EMT. The importance of EMT as a prognostic biomarker is explored and the rationale on application of multitargeted epigenetic therapy is discussed. We describe a literature review of the epigenetic influence of such process and we present a potentially effective method to reverse the epigenetic switch in favor for MET, in a clinical setting. A case series of advanced solid tumors are summarized aiming at generating hypothesis for the future recommendations for clinical trials targeting the tumor’s biological behavior through inhibition of EMT. Hypothesis: We propose an integral and integrative approach that can modify tumor’s biological behavior through inhibition of EMT, and further reduce the chances of metastasis, that can translate to improved outcome and patient’s survival in advanced disease.